Ralph Zitnik
Overview
Explore the profile of Ralph Zitnik including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
1324
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Gordon K, Korman N, Frankel E, Wang H, Jahreis A, Zitnik R, et al.
J Am Acad Dermatol
. 2006 Feb;
54(3 Suppl 2):S101-11.
PMID: 16488320
Background: The tumor necrosis factor (TNF) inhibitor etanercept has been demonstrated to be safe and effective for treating chronic plaque psoriasis in 3 clinical trials. Objectives: To refine efficacy results...
12.
Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy
Gordon K, Gottlieb A, Leonardi C, Elewski B, Wang A, Jahreis A, et al.
J Dermatolog Treat
. 2006 Feb;
17(1):9-17.
PMID: 16467018
Background: Although continuous therapy with the tumor necrosis factor (TNF) antagonist, etanercept, has been shown to have a favorable benefit to risk profile in the treatment of moderate to severe...
13.
Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, et al.
Lancet
. 2006 Jan;
367(9504):29-35.
PMID: 16399150
Background: Psoriasis has substantial psychological and emotional effects. We assessed the effect of etanercept, an effective treatment for the clinical symptoms of psoriasis, on fatigue and symptoms of depression associated...
14.
Nestorov I, Zitnik R, Ludden T
J Pharmacokinet Pharmacodyn
. 2005 Oct;
31(6):463-90.
PMID: 16222785
The objective of this paper is to present a population PK model which adequately describes the time-concentration profiles of different doses of ctanercept (Enbrel) administered subcutaneously to subjects with moderate-to-severe...
15.
Lebwohl M, Blum R, Berkowitz E, Kim D, Zitnik R, Osteen C, et al.
Arch Dermatol
. 2005 Jul;
141(7):861-4.
PMID: 16027301
Objective: To determine the incidence of cutaneous squamous cell carcinoma (SCC) in patients with rheumatoid arthritis receiving etanercept, a tumor necrosis factor antagonist, for up to 5 years. Design: An...
16.
Gottlieb A, Matheson R, Lowe N, Krueger G, Kang S, Goffe B, et al.
Arch Dermatol
. 2003 Dec;
139(12):1627-32.
PMID: 14676082
Objective: To determine safety and efficacy of monotherapy with etanercept. Design: Randomized, double-blind, placebo-controlled, multicenter study. Setting: Outpatient, ambulatory; private practice and university dermatology research centers. Patients: Patients aged at...
17.
Leonardi C, Powers J, Matheson R, Goffe B, Zitnik R, Wang A, et al.
N Engl J Med
. 2003 Nov;
349(21):2014-22.
PMID: 14627786
Background: Inflammatory cytokines such as tumor necrosis factor (TNF) have been implicated in the pathogenesis of psoriasis. We evaluated the safety and efficacy of etanercept, a TNF antagonist, for the...